Pasithea Capex To Revenue vs Price To Sales Ratio Analysis

KTTA Stock  USD 2.52  0.14  5.26%   
Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Capex To Revenue and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Capex To Revenue vs Price To Sales Ratio

Capex To Revenue vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Capex To Revenue account and Price To Sales Ratio. At this time, the significance of the direction appears to have pay attention.
The correlation between Pasithea Therapeutics' Capex To Revenue and Price To Sales Ratio is -0.91. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Capex To Revenue and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Pasithea Therapeutics Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Capex To Revenue i.e., Pasithea Therapeutics' Capex To Revenue and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.91
Relationship DirectionNegative 
Relationship StrengthSignificant

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Pasithea Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pasithea Therapeutics sales, a figure that is much harder to manipulate than other Pasithea Therapeutics Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At present, Pasithea Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 31 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 16.32.
 2010 2022 2023 2024 (projected)
Reconciled Depreciation1.4K32.4K517.7K543.5K
Cost Of Revenue17.3K113.2K648.5K680.9K

Pasithea Therapeutics fundamental ratios Correlations

0.530.71.00.93-0.96-0.630.680.980.980.940.860.950.911.00.99-0.250.98-0.25-0.42-0.420.6-0.42-0.42-0.42-0.42
0.530.80.520.8-0.35-0.940.940.460.460.740.470.70.730.520.46-0.950.43-0.95-0.94-0.990.18-0.94-0.99-0.99-0.99
0.70.80.680.88-0.54-0.940.920.570.570.90.80.890.930.680.58-0.660.55-0.66-0.62-0.770.66-0.62-0.76-0.74-0.76
1.00.520.680.92-0.97-0.610.670.990.990.930.850.940.91.00.99-0.230.98-0.23-0.41-0.40.59-0.41-0.4-0.41-0.4
0.930.80.880.92-0.81-0.870.90.870.870.990.840.980.980.920.87-0.580.85-0.58-0.69-0.720.56-0.69-0.72-0.72-0.72
-0.96-0.35-0.54-0.97-0.810.42-0.48-0.99-0.99-0.83-0.74-0.86-0.8-0.97-0.980.05-0.990.050.210.22-0.480.210.220.220.22
-0.63-0.94-0.94-0.61-0.870.42-1.0-0.51-0.51-0.85-0.7-0.81-0.86-0.61-0.520.85-0.480.850.860.92-0.510.860.920.910.92
0.680.940.920.670.9-0.48-1.00.580.580.880.730.840.880.670.58-0.830.55-0.83-0.87-0.910.5-0.87-0.91-0.91-0.91
0.980.460.570.990.87-0.99-0.510.581.00.870.770.890.830.991.0-0.161.0-0.16-0.36-0.330.48-0.36-0.33-0.34-0.33
0.980.460.570.990.87-0.99-0.510.581.00.870.770.890.830.991.0-0.161.0-0.16-0.36-0.330.48-0.36-0.33-0.34-0.33
0.940.740.90.930.99-0.83-0.850.880.870.870.91.00.990.930.88-0.50.86-0.5-0.6-0.650.66-0.6-0.65-0.65-0.65
0.860.470.80.850.84-0.74-0.70.730.770.770.90.890.90.850.78-0.220.76-0.22-0.38-0.380.91-0.38-0.38-0.39-0.38
0.950.70.890.940.98-0.86-0.810.840.890.891.00.890.990.940.89-0.460.87-0.46-0.55-0.610.65-0.55-0.61-0.6-0.61
0.910.730.930.90.98-0.8-0.860.880.830.830.990.90.990.90.84-0.50.81-0.5-0.57-0.660.68-0.57-0.65-0.64-0.65
1.00.520.681.00.92-0.97-0.610.670.990.990.930.850.940.90.99-0.230.98-0.23-0.41-0.40.59-0.41-0.4-0.41-0.4
0.990.460.580.990.87-0.98-0.520.581.01.00.880.780.890.840.99-0.161.0-0.16-0.36-0.330.49-0.36-0.33-0.34-0.33
-0.25-0.95-0.66-0.23-0.580.050.85-0.83-0.16-0.16-0.5-0.22-0.46-0.5-0.23-0.16-0.131.00.930.980.010.930.980.980.98
0.980.430.550.980.85-0.99-0.480.551.01.00.860.760.870.810.981.0-0.13-0.13-0.34-0.30.47-0.34-0.3-0.31-0.3
-0.25-0.95-0.66-0.23-0.580.050.85-0.83-0.16-0.16-0.5-0.22-0.46-0.5-0.23-0.161.0-0.130.930.980.010.930.980.980.98
-0.42-0.94-0.62-0.41-0.690.210.86-0.87-0.36-0.36-0.6-0.38-0.55-0.57-0.41-0.360.93-0.340.930.93-0.121.00.940.960.94
-0.42-0.99-0.77-0.4-0.720.220.92-0.91-0.33-0.33-0.65-0.38-0.61-0.66-0.4-0.330.98-0.30.980.93-0.130.931.01.01.0
0.60.180.660.590.56-0.48-0.510.50.480.480.660.910.650.680.590.490.010.470.01-0.12-0.13-0.12-0.13-0.13-0.13
-0.42-0.94-0.62-0.41-0.690.210.86-0.87-0.36-0.36-0.6-0.38-0.55-0.57-0.41-0.360.93-0.340.931.00.93-0.120.940.960.94
-0.42-0.99-0.76-0.4-0.720.220.92-0.91-0.33-0.33-0.65-0.38-0.61-0.65-0.4-0.330.98-0.30.980.941.0-0.130.941.01.0
-0.42-0.99-0.74-0.41-0.720.220.91-0.91-0.34-0.34-0.65-0.39-0.6-0.64-0.41-0.340.98-0.310.980.961.0-0.130.961.01.0
-0.42-0.99-0.76-0.4-0.720.220.92-0.91-0.33-0.33-0.65-0.38-0.61-0.65-0.4-0.330.98-0.30.980.941.0-0.130.941.01.0
Click cells to compare fundamentals

Pasithea Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(14.79)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.38)
Return On Equity
(0.63)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.